Preferred Label : aniline compounds;
MeSH definition : Compounds that include the aminobenzene structure.;
MeSH synonym : compounds, aniline; phenylamines; Anilines; Phenylamine;
MeSH annotation : DF: ANILINE CPDS;
Wikipedia link : https://en.wikipedia.org/wiki/Phenylamine;
Is substance : O;
Origin ID : D000814;
UMLS CUI : C0003038;
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Manual BTNT mappings - CISMeF
Record concept(s)
Related MeSH Supplementary Concept(s)
- 4,4'-(1E,1'E)-2,2'-(7,7'(1E,1'E)2,2'(4,4'-sulfonylbis(4,1-phenylene))bis(ethane-2,1-diyl)bis(9,9-didecy-9H-fluorene7,2-diyl))bis(ethane-2,1-diyl)bis(N,N-diphenylaniline) [MeSH Supplementary Concept]
- 4,4'-(9,9-di(2,5,8,11,14,17,20,23,26,29-decaoxahentriacontan-31-yl)-9H-fluorene-2,7-diyl)bis(ethyne-2,1-diyl)bis(N,N-dimethylaniline) [MeSH Supplementary Concept]
- AA 560 [MeSH Supplementary Concept]
- ABA 571 [MeSH Supplementary Concept]
- ANIS-AM [MeSH Supplementary Concept]
- AT-1012 [MeSH Supplementary Concept]
- AV 138 [MeSH Supplementary Concept]
- AZ 876 [MeSH Supplementary Concept]
- AZ683 [MeSH Supplementary Concept]
- AZD7507 [MeSH Supplementary Concept]
- AZD8186 [MeSH Supplementary Concept]
- BI-11A7 [MeSH Supplementary Concept]
- BI-2A7 [MeSH Supplementary Concept]
- BJ-1108 [MeSH Supplementary Concept]
- BM-1197 [MeSH Supplementary Concept]
- BO-0742 [MeSH Supplementary Concept]
- CB002 [MeSH Supplementary Concept]
- EKB 569 [MeSH Supplementary Concept]
- Fluo-3 [MeSH Supplementary Concept]
- Fura-4F [MeSH Supplementary Concept]
- GSK143 [MeSH Supplementary Concept]
- GW 4869 [MeSH Supplementary Concept]
- H8208 [MeSH Supplementary Concept]
- HR 325 [MeSH Supplementary Concept]
- JBIR-17 [MeSH Supplementary Concept]
- JK 273 [MeSH Supplementary Concept]
- JTR-009 [MeSH Supplementary Concept]
- LFM A12 [MeSH Supplementary Concept]
- LK-6062 [MeSH Supplementary Concept]
- MAY0132 [MeSH Supplementary Concept]
- ML-162 [MeSH Supplementary Concept]
- NC 1005 [MeSH Supplementary Concept]
- NC 1006 [MeSH Supplementary Concept]
- NTE 122 [MeSH Supplementary Concept]
- P 4000 [MeSH Supplementary Concept]
- PIK-108 [MeSH Supplementary Concept]
- PM-33 [MeSH Supplementary Concept]
- SA 6541 [MeSH Supplementary Concept]
- SU 0020 [MeSH Supplementary Concept]
- T 2591 [MeSH Supplementary Concept]
- THK5105 [MeSH Supplementary Concept]
- TR-764 [MeSH Supplementary Concept]
- TUG-469 [MeSH Supplementary Concept]
- TX 108 [MeSH Supplementary Concept]
- TX 109 [MeSH Supplementary Concept]
- URB 754 [MeSH Supplementary Concept]
- YNT-185 [MeSH Supplementary Concept]
- ZK 4044 [MeSH Supplementary Concept]
- afesal [MeSH Supplementary Concept]
- aniline [MeSH Supplementary Concept]
- eltenac [MeSH Supplementary Concept]
- fluo 4 [MeSH Supplementary Concept]
- ismine [MeSH Supplementary Concept]
- pentryl [MeSH Supplementary Concept]
Semantic type(s)
Compounds that include the aminobenzene structure.
2024
false
false
false
France
French
osimertinib
summary of product characteristics
package leaflet
guidelines for drug use
administration, oral
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
mutation
bronchial neoplasms
bronchial neoplasms
EGF Receptors
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
osimertinib
EGFR NP_005219.2:p.L858R
EGFR Exon 19 Deletion Mutation
ErbB Receptors
acrylamides
aniline compounds
---
https://www.has-sante.fr/jcms/p_3168614/fr/tagrisso
2020
false
false
false
France
administration, oral
adult
insurance, health, reimbursement
antineoplastic agents
protein kinase inhibitors
neoplasm metastasis
carcinoma, non-small-cell lung
bronchial neoplasms
Activating EGFR Gene Mutation
osimertinib
osimertinib
evaluation of the transparency committee
piperazines
acrylamides
aniline compounds
---
https://www.has-sante.fr/jcms/p_3192321/fr/xospata
2020
false
false
false
France
gilteritinib
gilteritinib
gilteritinib
administration, oral
insurance, health, reimbursement
treatment outcome
leukemia, myeloid, acute
guidelines for drug use
mutation
leukemia, myeloid, acute
survival analysis
FLT3 Gene Mutation
fms-like tyrosine kinase 3
recurrence
protein kinase inhibitors
protein kinase inhibitors
acute myeloid leukemia with FLT3 mutation
evaluation of the transparency committee
aniline compounds
pyrazines
aniline compounds
pyrazines
---
https://www.has-sante.fr/portail/jcms/c_2899212/fr/neuraceq
https://www.has-sante.fr/portail/jcms/c_2899212/fr/neuraceq-18f-florbetaben-radiopharmaceutique
2019
false
false
false
France
injections, intravenous
insurance, health, reimbursement
radiopharmaceuticals
18F-florbetaben
alzheimer disease
amyloid beta-Peptides
florbetaben (18F)
cognition disorders
Positron-Emission tomography
cerebrum
plaque, amyloid
adult
guidelines for drug use
evaluation of the transparency committee
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
aniline compounds
stilbenes
---
https://www.has-sante.fr/jcms/p_3097600/fr/bosulif
2019
false
false
false
France
bosutinib
administration, oral
treatment outcome
leukemia, myeloid, chronic-phase
Philadelphia chromosome positive chronic myelogenous leukemia (disorder)
antineoplastic agents
protein kinase inhibitors
bosutinib
adult
evaluation of the transparency committee
aniline compounds
nitriles
quinolines
---
https://www.has-sante.fr/jcms/p_3098041/fr/bosulif
2019
false
false
false
France
bosutinib
bosutinib
treatment outcome
adult
antineoplastic agents
protein kinase inhibitors
leukemia, myelogenous, chronic, bcr-abl positive
evaluation of the transparency committee
aniline compounds
nitriles
quinolines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/xospata
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
gilteritinib
gilteritinib
protein kinase inhibitors
protein kinase inhibitors
orphan drug production
adult
antineoplastic agents
antineoplastic agents
leukemia, myeloid, acute
administration, oral
continuity of patient care
FLT3 Gene Mutation
fms-like tyrosine kinase 3
FLT3 protein, human
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
gilteritinib
Tyrosine Kinase Inhibitors
aniline compounds
pyrazines
aniline compounds
pyrazines
---
https://pharmactuel.com/index.php/pharmactuel/article/view/1265
2019
false
false
false
false
France
comparative effectiveness research
treatment outcome
EGFR Gene Mutation
protein kinase inhibitors
protein-tyrosine kinases
antineoplastic agents
Gefitinib
Afatinib
clinical trials, phase iii as topic
antineoplastic agents
protein kinase inhibitors
lung neoplasms
lung neoplasms
carcinoma, non-small-cell lung
osimertinib
osimertinib
Tyrosine Kinase Inhibitors
critical appraisal or critical reading
carcinoma, non-small-cell lung
piperazines
piperazines
acrylamides
aniline compounds
acrylamides
aniline compounds
---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/1204
2018
false
false
false
Canada
French
osimertinib
due to
Pemetrexed
mutation
Chemotherapy
"u" lymphocyte
platinum
receptors, opioid, mu
platinum, nos
neoplasm, malignant
Cell
carcinoma, non-small-cell lung
small cell lung carcinoma
drug therapy
base, nos
chemotherapy, nos
treaties
Lung cancer
chemotherapy
small cell lung carcinoma
international cooperation
piperazines
ErbB Receptors
acrylamides
aniline compounds
acrylamides
aniline compounds
---
https://www.anses.fr/fr/system/files/VSR2016SA0119Ra.pdf
2018
false
false
false
France
French
technical report
chronic
inlets
respiratory tract
threshold limit values
chronic disease
3-chloroaniline
relative
albumin/globulin ratio
Colorectal adenoma
4-chloroaniline
Acne fulminans
Metabolic acidosis
report
Bronchopulmonary adenocarcinoma
Acne keloidalis
Mucinous adenocarcinoma
chloroaniline
administration, oral
bays
respiratory system
research report
aniline compounds
---
https://www.has-sante.fr/portail/jcms/c_2794988/fr/tagrisso-osimertinib-inhibiteur-de-tyrosine-kinase
https://www.has-sante.fr/portail/jcms/c_2794988/fr/tagrisso
2017
false
false
false
false
France
French
treatment outcome
piperazines
adult
carcinoma, non-small-cell lung
Advanced Malignant Neoplasm
neoplasm metastasis
mutation
antineoplastic agents
carcinoma, non-small-cell lung
administration, oral
protein kinase inhibitors
Tyrosine Kinase Inhibitor
protein-tyrosine kinases
evaluation of the transparency committee
insurance, health, reimbursement
survival analysis
osimertinib
guidelines for drug use
EGFR NP_005219.2:p.T790M
comparative effectiveness research
osimertinib
Tyrosine Kinase Inhibitors
ErbB Receptors
acrylamides
aniline compounds
---
http://www.has-sante.fr/portail/jcms/c_2753721/fr/vizamyl
http://www.has-sante.fr/portail/jcms/c_2753721/fr/vizamyl-flutemetamol-18f-produit-diagnostique-pour-le-systeme-nerveux-central
2017
false
false
false
France
French
treatment outcome
flutemetamol
(18F)flutemetamol
flutemetamol (18F)
radiopharmaceuticals
Positron-Emission tomography
plaque, amyloid
cerebrum
dementia
alzheimer disease
injections, intravenous
evaluation of the transparency committee
insurance, health, reimbursement
guidelines for drug use
aniline compounds
benzothiazoles
plaque, amyloid
cerebrum
alzheimer disease
dementia
---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BCR-ABL-Imatinib-Dasatinib-Nilotinib-Bosutinib-Ponatinib-Medicament-ciblant-JAK-Ruxolitinib-Anticancereux-par-voie-orale-informer-prevenir-et-gerer-leurs-effets-indesirables
2016
false
false
false
France
French
practice guideline
antineoplastic agents
administration, oral
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
information dissemination
patient education as topic
drug interactions
Dasatinib
Imatinib Mesylate
fusion proteins, bcr-abl
protein kinase inhibitors
dasatinib
imatinib
nilotinib
nilotinib
bosutinib
ponatinib
ruxolitinib
janus kinases
ponatinib
ruxolitinib
bosutinib
continuity of patient care
pregnancy
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
pyrimidines
pyrazoles
---
http://www.has-sante.fr/portail/jcms/c_2676714/fr/tagrisso
http://www.has-sante.fr/portail/jcms/c_2676714/fr/tagrisso-osimertinib-inhibiteur-de-tyrosine-kinase
2016
false
false
false
France
French
treatment outcome
piperazines
adult
carcinoma, non-small-cell lung
Advanced Malignant Neoplasm
neoplasm metastasis
mutation
antineoplastic agents
carcinoma, non-small-cell lung
administration, oral
protein kinase inhibitors
Tyrosine Kinase Inhibitor
protein-tyrosine kinases
evaluation of the transparency committee
insurance, health, reimbursement
survival analysis
osimertinib
guidelines for drug use
EGFR NP_005219.2:p.T790M
osimertinib
Tyrosine Kinase Inhibitors
ErbB Receptors
acrylamides
aniline compounds
---
BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib),
BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk
of Hepatitis B Reactivation
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
fusion proteins, bcr-abl
protein kinase inhibitors
Imatinib Mesylate
risk
hepatitis b virus
imatinib
nilotinib
nilotinib
bosutinib
bosutinib
Dasatinib
dasatinib
ponatinib hydrochloride
ponatinib
Tyrosine Kinase Inhibitor
Hepatitis B reactivation
guidelines for drug use
continuity of patient care
mass screening
hepatitis B
hepatitis B
Tyrosine Kinase Inhibitors
nilotinib
ponatinib
pyrimidines
imidazoles
pyridazines
aniline compounds
nitriles
quinolines
---
https://www.ema.europa.eu/medicines/human/EPAR/Tagrisso
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
piperazines
piperazines
pregnancy
breast feeding
drug interactions
adult
carcinoma, non-small-cell lung
Advanced Malignant Neoplasm
neoplasm metastasis
mutation
antineoplastic agents
antineoplastic agents
carcinoma, non-small-cell lung
genetic testing
administration, oral
protein kinase inhibitors
protein kinase inhibitors
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor
protein-tyrosine kinases
product surveillance, postmarketing
drug monitoring
contraception
drug evaluation, preclinical
osimertinib
osimertinib
osimertinib
Tyrosine Kinase Inhibitors
ErbB Receptors
acrylamides
aniline compounds
acrylamides
aniline compounds
---
http://www.e-cancer.fr/content/download/126025/1524695/file/Médicaments%20ciblant%20BCR-ABL.pdf
2015
false
false
false
France
French
practice guideline
guidelines for drug use
administration, oral
antineoplastic agents
Drug-Related side effects and adverse reactions
imatinib
dasatinib
nilotinib
nilotinib
bosutinib
bosutinib
ponatinib
ponatinib
protein kinase inhibitors
ruxolitinib
ruxolitinib
janus kinases
information dissemination
continuity of patient care
hospital-physician relations
hospital-patient relations
physician-patient relations
drug interactions
pregnancy
protein-tyrosine kinases
Tyrosine Kinase Inhibitor
Dasatinib
Imatinib Mesylate
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
pyrazoles
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
---
https://ansm.sante.fr/tableau-atu-rtu/azd9291-40-et-80-mg-comprime-pellicule
2015
false
false
false
France
French
adult
pharmacovigilance
continuity of patient care
acrylamides
acrylamides
aniline compounds
aniline compounds
administration, oral
carcinoma, non-small-cell lung
Locally Advanced Malignant Neoplasm
antineoplastic agents
antineoplastic agents
Stage IV Lung Non-Small Cell Cancer AJCC v7
neoplasm metastasis
EGFR Gene Mutation
osimertinib
drug information
AZD9291
ErbB Receptors
---
http://www.has-sante.fr/portail/jcms/c_1730843/fr/bosulif-bosutinib-inhibiteur-de-tyrosine-kinase
2014
false
false
false
France
French
English
evaluation of the transparency committee
guidelines for drug use
administration, oral
bosutinib
bosutinib
bosutinib
adult
leukemia, myeloid, chronic-phase
leukemia, myeloid, accelerated phase
blast crisis
protein kinase inhibitors
protein kinase inhibitors
insurance, health, reimbursement
treatment outcome
survival analysis
aniline compounds
nitriles
quinolines
aniline compounds
nitriles
quinolines
---
http://www.has-sante.fr/portail/jcms/c_1720113/fr/amyvid
2014
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
florbetapir F 18
Positron-Emission tomography
adult
plaque, amyloid
cognition disorders
amyloid beta-Peptides
alzheimer disease
cerebrum
cerebrum
florbetapir (18F)
diagnostic uses of chemicals
florbetapir
aniline compounds
ethylene glycols
cerebrum
cognition disorders
alzheimer disease
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=63150294
2014
false
false
false
France
French
summary of product characteristics
package leaflet
bosutinib
bosutinib
tablets
pill, nos
compression, nos
bosutinib
dandruff
seborrhea sicca
dandruff
aniline compounds
nitriles
quinolines
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60462965
2014
false
false
false
France
French
summary of product characteristics
package leaflet
pill, nos
compression, nos
bosutinib
bosutinib
seborrhea sicca
tablets
dandruff
bosutinib
dandruff
aniline compounds
nitriles
quinolines
---
https://www.ema.europa.eu/medicines/human/EPAR/Vizamyl
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
flutemetamol
flutemetamol
(18F)flutemetamol
(18F)flutemetamol
flutemetamol (18F)
radiopharmaceuticals
radiopharmaceuticals
Positron-Emission tomography
plaque, amyloid
cerebrum
dementia
alzheimer disease
product surveillance, postmarketing
injections, intravenous
pregnancy
breast feeding
drug evaluation, preclinical
lewy body disease
parkinson disease
aniline compounds
benzothiazoles
aniline compounds
benzothiazoles
plaque, amyloid
cerebrum
alzheimer disease
dementia
lewy body disease
---
http://www.inrs.fr/accueil/produits/bdd/doc/fichetox.html?refINRS=FT%20218
France
French
aniline compounds
aniline compounds
aniline compounds
aniline compounds
aniline compounds
occupational exposure
occupational diseases
reference values
4,4'-diaminodiphenylmethane
guidelines
toxicological data sheet
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=141309&nom=Thiodianiline%2D4%2C4%27
Canada
French
aniline compounds
4,4'-thiodianiline
toxicological data sheet
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=116210&nom=Dim%E9thyl%2D2%2C6+aniline
Canada
French
aniline compounds
2,6-xylidine
toxicological data sheet
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=87858&nom=Diamino%2D4%2C4%27+diph%E9nylm%E9thane
Canada
French
aniline compounds
carcinogens
4,4'-diaminodiphenylmethane
toxicological data sheet
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=125203&nom=M%E9thyl%E8nebis%28N%2CN%2Ddim%E9thylbenz%E8namine%29%2D4%2C4%27+++
Canada
French
aniline compounds
N,N,N',N'-tetramethyl-4,4'-methylenedianiline
toxicological data sheet
---
http://www.inrs.fr/accueil/produits/bdd/doc/fichetox.html?refINRS=FT%2019
2009
France
French
reference values
aniline compounds
aniline compounds
aniline compounds
aniline compounds
aniline compounds
occupational exposure
occupational diseases
aniline
guidelines
toxicological data sheet
---